Literature DB >> 9244138

Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity?

P Macheras1, P Argyrakis.   

Abstract

The current analysis of gastrointestinal absorption phenomena relies on the concept of homogeneity. However, drug dissolution, transit and uptake in the gastrointestinal tract are heterogeneous processes since they take place at interfaces of different phases under variable stirring conditions. Recent advances in physics and chemistry demonstrate that the geometry of the environment is of major importance for the treatment of heterogeneous processes. In this context, the heterogeneous character of in vivo drug dissolution, transit and uptake is discussed in terms of fractal concepts. Based on this analysis, drugs are classified in accordance with their gastrointestinal absorption characteristics into two broad categories i.e. homogeneous and heterogeneous. The former category includes drugs with satisfactory solubility and permeability which ensure the validity of the homogeneous hypothesis. Drugs with low solubility and permeability are termed heterogeneous since they traverse the entire gastrointestinal tract and therefore are more likely to exhibit heterogeneous dissolution, transit and uptake. The high variability of whole bowel transit and the unpredictability of conventional dissolution tests for heterogeneous drugs are interpreted on the basis of the fractal nature of these processes under in vivo conditions. The implications associated with the use of strict statistical criteria in bioequivalence studies for heterogeneous drugs are also pointed out.

Entities:  

Mesh:

Year:  1997        PMID: 9244138     DOI: 10.1023/a:1012183313218

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

1.  A heterogeneous tube model of intestinal drug absorption based on probabilistic concepts.

Authors:  A Kalampokis; P Argyrakis; P Macheras
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

Review 2.  Nonlinear dynamics and chaos theory: concepts and applications relevant to pharmacodynamics.

Authors:  A Dokoumetzidis; A Iliadis; P Macheras
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

3.  Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio.

Authors:  Eleni Rinaki; Georgia Valsami; Panos Macheras
Journal:  Pharm Res       Date:  2003-12       Impact factor: 4.200

4.  A new wet conductivimetric method to estimate the drug percolation threshold.

Authors:  Alvaro Espina-Márquez; Isidoro Caraballo
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

5.  The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs.

Authors:  Mehran Yazdanian; Katherine Briggs; Corinne Jankovsky; Amale Hawi
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

6.  Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS.

Authors:  Georgia Charkoftaki; Aristides Dokoumetzidis; Georgia Valsami; Panos Macheras
Journal:  Pharm Res       Date:  2012-07-04       Impact factor: 4.200

7.  Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. I: conceptual and numerical issues.

Authors:  J Popović
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

Review 8.  Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts.

Authors:  K Sandy Pang; Michael Weiss; Panos Macheras
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

9.  Fractional kinetics in drug absorption and disposition processes.

Authors:  Aristides Dokoumetzidis; Panos Macheras
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-04-02       Impact factor: 2.745

10.  A new approach to the compartmental analysis in pharmacokinetics: fractional time evolution of diclofenac.

Authors:  Jovan K Popović; Milica T Atanacković; Ana S Pilipović; Milan R Rapaić; Stevan Pilipović; Teodor M Atanacković
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-01-14       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.